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Abstract
Background: Several autoimmune skin disorders are characterised by an increased risk of thrombosis, with bollous
pemphigoid carrying a higher risk than pemphigus vulgaris (PV). We describe the case of a middle aged gentleman
who developed recurrent venous thromboembolism despite adequate oral anticoagulation during very active PV
that required escalation of treatment to bring the disease under control.
Case presentation: In May 2014 a 49 year gentleman was admitted for widespread mucocutaneous blistering
diagnosed as PV by histology and immunofluorescence. After 6 weeks of treatment with systemic steroids and
azathioprine the patient developed pulmonary emboli and started oral anticoagulation with warfarin. In late
September, the patient re-presented with a severe flare of PV and a recurrent deep vein thrombosis despite oral
anticoagulation within therapeutic range. Warfarin was changed to subcutaneous low molecular heparin in
therapeutic dose while treatment for pemphigus was escalated: first azathioprine was switched to mycophenolate
mofetil and the steroids dose increased; then due to poor response, intravenous immunoglobulins were given for
three courses and finally he received four infusions of Rituximab that induced sustained remission. In April 2015
the dose of mycophenolate was decreased but anticoagulation was continued until the beginning of July 2015
to ensure that decreasing immune suppression did not allow the emergence of another flare with attendant
thrombotic risk.
Conclusion: The case highlights the risk of thrombosis and re-thrombosis in aggressive PV and demands further
clinical research in this area to assess the need for thromboprophylaxis in aggressive bollous skin disease.
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Background
Pemphigus vulgaris (PV) is an autoimmune skin dis-
order characterized clinically by intra epidermal blisters
and erosions due to an immunoglobulin G autoantibody
with specificity against the desmosomal desmogleins 3
and 1 [1]. PV is also characterised by an increased
thrombotic risk as highlighted by the Oxford Record
Linkage Study in PV patients admitted to hospital [2],
though coagulation activation in PV is not enhanced as
in bullous pemphigoid [3]. We describe herein a patient
with PV who developed pulmonary embolism (PE) first
then recurrent venous thromboembolism (VTE) despite
adequate oral anticoagulation during the course of very
active PV.
Case presentation
A 49 year gentleman was admitted in May 2014 to the
dermatology ward for widespread blistering around his
groins then spreading to mouth, nose, torso, penis and
scalp. A skin biopsy revealed intradermal acantolytic
blisters by conventional microscopy and strong intrader-
mal cellular staining for pemphigus antigens by im-
munofluorescence microscopy in keeping with PV
(Fig. 1). ANA, c-ANCA and p-ANCA were negative. He
commenced treatment with topical and systemic steroids
and azathioprine. Before this admission he had
always been fit and well, with no personal or family his-
tory of VTE and was ambulant during his admission. Six
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weeks later the patient developed bilateral PE and
started anticoagulation with therapeutic Deltaparin
switched then to warfarin that was monitored in the
community at fortnightly intervals with international
normalised ratio (INR) between 2.3 and 2.9. After
9 weeks, in late September, the patient re-presented with
a severe flare of PV and a swollen left leg despite being
in an adequate therapeutic range, the INR being 2.5 two
weeks before recurrent event and INR 2.7 at recurrent
event: a doppler ultrasound revealed a superficial fem-
oral vein occlusion. The dose of systemic steroids was
increased and azathioprine was switched to mycopheno-
late mofetil 1.5 g bd: because his recurrent VTE hap-
pened whilst he was in therapeutic INR, warfarin was
switched to low molecular weight heparin at treatment
dose to be continued for no less than 6 months from the
VTE. Owing to poor PV response in late October the
patient received one monthly infusion of intravenous
immunoglobulin (0.5 mg/kg over 5 days) for a total of
three courses. In January 2015 he received four infusions
of Rituximab (375 mg/m2) at weekly intervals that
brought his PV under control. He remained on oral my-
cophenolate 1.5 g bd until April 2015 when it was
decreased to 1.0 g bd: to ensure that the decrease of
immunosuppressant dose did not favour a disease flare
with a new recurrent VTE his anticoagulation was con-
tinued up to the beginning of July 2015 instead of stop-
ping after 6 months. A thrombophilia screen including
Factor V Leiden, Prothrombin 20210 mutation, anti-
thrombin, protein C and S, anticardiolipin antibodies
and lupus anticoagulant performed after cessation of
anticoagulation was normal. At his last follow up in
mid-December 2015 the patient was in sustained remis-
sion on mycophenolate 1.0 g bd.
Conclusion
Our patient developed PE during the initial phase of his
extensive and aggressive PV that was initially managed
with azathioprine and steroids plus warfarin leading to a
transient remission. At 9 weeks from the PE the patient
represented with a severe flare of PV and a recurrent
VTE despite adequate anticoagulation. The activity of
PV required several sequential changes and/or addition
of medications before it was decided to offer him Rituxi-
mab not without some concerns [4] but this finally
brought the patient into remission. At the recurrence of
VTE direct oral anticoagulants were not taken into ac-
count to minimise the perceived bleeding risk on a
mucosa and skin that were still actively inflamed and
to avoid the remote possibility of a skin reaction;
hence the switch from warfarin to low molecular
weight heparin. The negative thrombophilia screen
strengthens the case of our active PV patient being in
a pro-thrombotic state despite a study showing that
neither active or inactive PV were associated with co-
agulation activation (3).
Other cases of VTE have been described in associ-
ation with PV in the English literature: these affected
lungs [5, 6], lung with deep veins, cardiac chambers
with myocardial infarction [7] and a further VTE
attributed to the use of intravenous immunoglobulins
to treat PV [8]. The odds of developing VTE in PV are
3.28 according to a record-linkage study over the
period 1999 to 2008 [2]. This is the first case of recur-
rent VTE developing in a patient with PV despite
adequate anti vitamin K anticoagulation and with no
other VTE risk factors. In the light of ours and other
available cases and owing to the elevated odds of the
record linkage study, further studies are needed to
evaluate whether thromboprophylaxis should be of-
fered to patients with aggressive PV until their disease
is better controlled to minimise the risk of vascular
complications.
Consent
Informed consent was obtained the participant of this
case study.
Fig. 1 Histology of skin biopsy showing: a) Light microscopy showing intradermal acantolytic blisters; b) Immunofluorescence showing
intradermal cellular staining for desmogleins 3
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